Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Retained Earnings: 2019-2023

Historic Retained Earnings for ADC Therapeutics (ADCT) over the last 4 years, with Sep 2023 value amounting to -$1.2 billion.

  • ADC Therapeutics' Retained Earnings fell 16.90% to -$1.2 billion in Q3 2023 from the same period last year, while for Sep 2023 it was -$1.2 billion, marking a year-over-year decrease of 16.90%. This contributed to the annual value of -$1.1 billion for FY2022, which is 18.44% down from last year.
  • Latest data reveals that ADC Therapeutics reported Retained Earnings of -$1.2 billion as of Q3 2023, which was down 4.03% from -$1.2 billion recorded in Q2 2023.
  • ADC Therapeutics' 5-year Retained Earnings high stood at -$58 for Q2 2019, and its period low was -$1.2 billion during Q3 2023.
  • Moreover, its 3-year median value for Retained Earnings was -$1.0 billion (2022), whereas its average is -$1.0 billion.
  • Data for ADC Therapeutics' Retained Earnings shows a maximum YoY plummeted of 1,066,455.17% (in 2020) over the last 5 years.
  • Over the past 5 years, ADC Therapeutics' Retained Earnings (Quarterly) stood at -$448.6 million in 2019, then crashed by 725,956.82% to -$638,930 in 2020, then crashed by 139,274.27% to -$924.9 million in 2021, then decreased by 18.44% to -$1.1 billion in 2022, then fell by 16.90% to -$1.2 billion in 2023.
  • Its Retained Earnings was -$1.2 billion in Q3 2023, compared to -$1.2 billion in Q2 2023 and -$1.1 billion in Q1 2023.